Matthew Dowling, Ph.D., is the CEO and co-founder of Remedium Technologies. Dowling completed his graduate work at the Fischell Department of Bioengineering at the University of Maryland in May 2010 and has since pursued RTI on a full-time basis. In 2005, he was awarded the Fischell Fellowship in Biomedical Engineering for his ideas for commercially viable drug delivery systems after graduating in chemical engineering at the
niversity of Notre Dame. At UMD, he developed the platform Hemogrip™ technology, which acts as the cornerstone of Remedium’s R&D pipeline for hemostasis and wound healing products.
The appearance of an author or a presenter on this DTIC website should not necessarily be construed as association of this individual with the United States Department of Defense (DoD), and the views, information, or opinions expressed herein are those of the author or presenter and do not necessarily constitute endorsement by the United States Department of Defense (DoD).